BMI1 and cancer: In this context, it has been found that BMI-1 inhibition increases the sensitivity of head and neck CSCs to cisplatin [37] and that cisplatin resistance is due to the ability of BMI-1 to promote cancer cell growth and proliferation by activating the PI3K/Akt-dependent pathway [83].